• WCG’s eCOA portfolio and imaging analysis technology from NeuroRx are now part of Clario!

menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Live
        • eCOA Multimedia
        • eCOA Rapid Start
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Frequently Asked Questions: 2023 EMA and FDA Guidance

Frequently Asked Questions: 2023 EMA and FDA Guidance

Unraveling the implications and intricacies of recent regulatory guidance: from screenshot requirements to patient-focused drug development and beyond

Bryan McDowell, M.Sc., M.B.A. – VP, eCOA Science and Consulting at Clario

In a recent LinkedIn poll, we asked our followers about their awareness of new eCOA-related regulatory guidance published this year. With over 140 responses, more than half indicated low to fairly low awareness. In a recent webinar, Bryan McDowell, Clario’s VP of eCOA Clinical Science and Consulting, delved into pivotal questions from clinical trial teams. Responses have been edited for clarity.

Q: Are screenshots for eCOA a critical part of IRB submission?

A: There has been a shift in mindset regarding the necessity of screenshots as we transition from paper to electronic records. While there was high demand for screenshots in the past, with various modalities and devices emerging, screenshots have become less important. The need for screenshots varies across countries and institutions. Regulatory authorities and ethics committees may review translations or IT implementations, but these processes shouldn’t rely solely on screenshots. Complex tools and devices make providing screenshots for all scenarios unrealistic. Instead, demonstrating proper implementation processes can alleviate the need for screenshots.

Q: How does the FDA’s Patient-Focused Drug Development guidance Part 4 address the issue of patient burden and how can we avoid missing data? What are the key differences between the FDA and the Patient Focused Guidance series and the FDA’s PRO guidance that came out in 2009?

A: The FDA’s Patient-Focused Drug Development (PFDD) series emphasizes patient input throughout drug development. It focuses on increasing participation convenience and value for patients, therefore lessening patient burden. The PFDD guidance is more comprehensive than the 2009 PRO guidance, offering detailed steps for gathering patient input throughout drug development, not just for labeling claims. When final, the PFDD series is expected to replace the 2009 guidance, while maintaining the principle of patient-centric drug development.

Q: Why is the latest patient document submission so complex?

A: The complexity arises from variations in national regulations across European countries. Although clear principles exist in Good Clinical Practices (GCP), implementation of these principles in national regulations leads to complexity. Patient documents must be categorized as fitting Part 1 or Part 2 of the PFDD, which varies based on different countries’ expectations. Over time, this complexity is expected to stabilize as regulations evolve.

Q: If we record the audit trail, even during a PRO-completion, how will we know if the initial entry was a tapping error or a hesitation from a patient? And what would we do with this data?

A: Audit trails pose challenges when patients make changes during completion. The requirement to document why and when a change occurs is unrealistic for patient-entered data like tapping errors or hesitations. This highlights the impracticality of audit trails for patient inputs made before questionnaire completion.

Q: There’s a feeling that decentralized trials are being pushed too hard and sometimes they’re not appropriate. What is the advice there?

A: The appropriateness of decentralized trials depends entirely on study design and objectives. Patient accessibility, safety, and scientific rigor are crucial. Science should guide trial design, determining whether decentralized elements align with the study’s goals. A flexible approach is key, considering various factors and evaluating if decentralized elements are suitable.

Q: What is the maximum amount of paper that could be used in a clinical trial that would be acceptable by regulators?

A: Minimizing paper is crucial to maintaining data quality. While exceptions exist, advocates discourage using paper, as it can degrade the quality of electronically collected data. In oncology, accurate early-stage data is particularly important, as these studies often support drug approvals.

As the eCOA landscape evolves, it’s essential to stay informed about regulatory guidance and adopt a strategic approach to electronic data collection. Understanding the nuances of these guidelines can greatly improve clinical trial efficiency and data quality.

Learn More
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Researcher spotlight: Dr. Lauren Tueth

Precision Motion

Read
Article

Researcher spotlight: Brice Cleland

Precision Motion

Read
Article

Researcher spotlight: Josefa Domingos

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum